EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Soluble CD206 in metastatic renal cell carcinoma: Relation to clinical–biochemical parameters and patient outcome

Kasper Munch Lauridsen iD, Holger Jon Møller, Mie Wolff Kristensen, Niels Fristrup, Frede Donskov, Marianne Hokland iD, Morten Nørgaard Andersen iD

International Journal of Cancer · 15.02.2025 · 156 (4) · 875-885

DOI: 10.1002/ijc.35194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 25.09.2024. Verfasst von Kasper Munch Lauridsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Receptors, Cell Surface, Kidney Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Biomedicine, Aarhus University, Independent Research Fund Denmark, Danish Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mannose receptor (MR/CD206) is a marker of M2‐like tumor‐associated macrophages. Membrane CD206 can be shed, releasing the receptor as a soluble protein (sCD206), which can be measured in serum. Here, we investigated the biomarker potential of sCD206 in patients with metastatic renal cell carcinoma (mRCC). Serum sCD206 was measured by an enzyme‐linked immunosorbent assay in 88 mRCC patients and 20 healthy controls (HCs). At diagnosis, serum sCD206 was elevated in patients with intermediate‐risk mRCC according to the Memorial Sloan Kettering Cancer Center (MSKCC) risk score, compared to both HCs and patients with favorable MSKCC risk score. Furthermore, sCD206 levels correlated with both sCD163 and C‐reactive protein. Soluble CD206 levels decreased after treatment initiation ( p < .0001 at 5 weeks) but with a tendency toward elevated levels at time of progression, compared to baseline ( p = .06). In univariate survival analysis, high levels of serum sCD206 at baseline was a significant risk factor associated with reduced overall survival (hazard ratio [HR] = 1.37, 95% confidence interval: 1.12–1.67, p = .002). Stratified by clinical risk scores, increased sCD206 was still a statistically significant risk factor of overall mortality ( p < .01) in the intermediate‐risk group by both the MSKCC (HR = 1.48) and the newer International Metastatic RCC Database Consortium (IMDC) score (HR = 1.53). Furthermore, addition of sCD206 as a dichotomized variable to the IMDC risk score enabled separation of the intermediate‐risk group into two groups with survival comparable to those with favorable and poor risk, respectively. Overall, sCD206 is a potential add‐on biomarker for mRCC patients in the intermediate‐risk group of the current clinical risk scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellReceptors, Cell SurfaceKidney NeoplasmsBiomarkers, TumorMannose ReceptorMannose-Binding LectinsHumansMaleFemaleMiddle AgedAgedAdultLectins, C-TypePrognosisCase-Control StudiesAged, 80 and over

Stichwörter der Autor:innen

CD206biomarkermacrophagesrenal cell carcinomasoluble CD206

Substanzen

Receptors, Cell SurfaceBiomarkers, TumorMannose ReceptorMannose-Binding LectinsLectins, C-Type

Autor:innen und Institutionen

  • Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark.
  • Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Kasper Munch Lauridsen, Marianne Hokland, Morten Nørgaard Andersen

Förderung

  • Department of Biomedicine, Aarhus University
  • Independent Research Fund Denmark
  • Danish Cancer Society
  • Central Denmark Region Health Research Foundation
  • Department of Clinical Medicine, Aarhus University
  • Department of Clinical Biochemistry, Aarhus University Hospital
  • Danmarks Frie Forskningsfond
  • Kræftens Bekæmpelse

Zitieren

APA

Lauridsen, K. M., Møller, H. J., Kristensen, M. W., Fristrup, N., Donskov, F., Hokland, M., & Andersen, M. N. (2025). Soluble CD206 in metastatic renal cell carcinoma: Relation to clinical–biochemical parameters and patient outcome. International Journal of Cancer, 156(4), 875-885. https://doi.org/10.1002/ijc.35194

Vancouver

Lauridsen KM, Møller HJ, Kristensen MW, Fristrup N, Donskov F, Hokland M, et al. Soluble CD206 in metastatic renal cell carcinoma: Relation to clinical–biochemical parameters and patient outcome. International Journal of Cancer. 2025;156(4):875-885. doi:10.1002/ijc.35194

BibTeX
@article{Lauridsen2025,
  author = {Lauridsen, Kasper Munch and Møller, Holger Jon and Kristensen, Mie Wolff and Fristrup, Niels and Donskov, Frede and Hokland, Marianne and Andersen, Morten Nørgaard},
  title = {Soluble CD206 in metastatic renal cell carcinoma: Relation to clinical–biochemical parameters and patient outcome},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {156},
  number = {4},
  pages = {875--885},
  doi = {10.1002/ijc.35194}
}
Kostenlos starten →